• karuselli2
  • karuselli5
  • karuselli3
  • karuselli1
  • karuselli6
  • karuselli4

Pediatric Research Center

The Pediatric Research Center currently represents almost 30 research groups carrying out clinical, translational and basic research in pediatrics in the University of Helsinki, Finland. Our mission is to promote research, to communicate the latest research results to physicians, patients and the general public, and to serve as a reference guide for researchers and companies seeking academic collaboration.  We warmly invite students and young physician-scientists to join our growing team!

NEW INSIGHTS INTO RSV DISEASE

In developed countries respiratory syncytial virus (RSV) causes busy epidemics during winter seasons but fortunately with very low levels of mortality in children. However, in developing countries the situation is different. In a recent meta-analysis it was estimated that globally RSV causes more than 100 000 deaths in children <5 years of age every year (Shi et al. Lancet 2017) and RSV is considered the second most important pathogen causing mortality in children only after malaria (Lozano et al. 2012 Lancet). This is something that we pediatricians in Finland and other developing countries often forget when we worry about crowded emergency departments, overfilled wards and busy on call shifts every winter during RSV epidemics.

Despite decades of research efforts there are no vaccines against or effective antivirals available for RSV. Vaccine development has been challenging after unfortunate clinical trials with inactivated RSV vaccine in 1960s, which not only failed to protect children from RSV but also caused enhanced disease in RSV naïve children with two study participants dying due to severe disease. Furthermore, as natural infection with RSV fails to produce protective immune response leading to re-infections throughout lifetime, inducing protective immunity will be a challenge also for the vaccine development. We still lack complete understanding of the immunological mechanisms contributing to increased disease severity and poor immune responses in children with RSV.

During my post doctoral training I worked in Nationwide Children’s Hospital in Columbus, Ohio in Asuncion Mejias’ and Octavio Ramilo’s group focusing on immunological host responses in children with viral respiratory tract infections. We used systems analysis approach with an aim to combine flow cytometry derived cellular immunophenotype data and transcriptomic data from peripheral white blood cells with detailed clinical and microbiological data.

In Columbus, we used microarray based methods for the transcriptome analyses but in the past few years more powerful methods have been developed. Microarray based methods have been replaced by RNA sequencing (RNAseq) and advances in microfluidics and nanotechnology have enabled transcriptome analyses at single cell level. Earlier we analyzed pooled RNA from large number of cells but these novel methods allow us to simultaneously obtain thousands of single cell transcriptomes from each patient sample.

After returning from Columbus a few years ago, I first wanted to focus on clinical work in order to advance my pediatric residency but I soon found myself planning new research projects. During the past winter season we started enrolling infants with RSV bronchiolitis in our study where we aim to take advantage of novel methods and use single cell RNAseq to gain better understanding of the host immune responses during RSV infection. The study will be conducted in collaboration with Päivi Saavalainen’s group from the University of Helsinki. Now that the RSV epidemic is over for this year, we will continue to enroll healthy controls. What constantly keeps amazing me is the positive attitude of the parents towards our study and research in general. Even if our study has no potential to help their sick child, they are willing to participate in order to help other children in the future. None of the parents we’ve approached so far have declined to participate in our study and we are truly thankful to all participating families.

I feel privileged to be able to continue research activities in parallel with my pediatric residency. For this I’m grateful for the flexibility of my supervisors in the Children’s Hospital and our residency program in the University of Helsinki and for the support from the Pediatric Research Center.

A NOVEL THERAPY TRIAL FOR AGU DISEASE AT HUCH

We have recently started a novel investigator initiated therapy trial for AGU (aspartylglucosaminuria) with betaine in HUCH child neurology clinic. It is performed in collaboration with Prof. Ritva Tikkanen, University of Giessen. AGU is a progressive disease leading to mental retardation due to the accumulation of aspartylglucosamine in all tissues and also in the brain. It belongs to the Finnish disease heritage, and most of the patients are from Finland (about 160 alive patients). AGU disease is diagnosed by urine oligosaccharides at the average age of five, when global developmental delay is noticed. (Read more)

Monogenic primary immunodeficiencies reveal new concepts of immune regulation

Rapid development of next generation sequencing (NGS) technologies and decreased costs of the whole exome and genome sequencing coupled with modern biochemistry and cellular biology methodology, have made identification of novel disease-causing gene mutations routine. Primary immunodeficiency diseases (PIDDs) are a clinically heterogeneous group of clinical entities caused by mutations in the genes which control the immune responses. Most of the PIDDs are monogenic rare disorders that follow Mendelian inheritance. (Read more)

New treatment options for neuromuscular diseases

We really live in a changing world of medicine. Majority of research in medicine aims at seeking new and better treatment options. All neuromuscular diseases are rare diseases, and most of them without specific treatments. Now first medicines for the most common childhood-onset neuromuscular diseases, Duchenne muscular dystrophy and spinal muscular atrophy, have become available, and novel therapies have filled the community with hope, but at the same time new questions and concerns have raised – is it safe? Is it really effective? Is it cost-beneficial? Is it ethical? Is it equal? (Read more)

Pediatric Research Center Academic Track Program

Pediatric Research Center Academic Track Program at the Helsinki University Hospital (HUH) is intended for young researchers with MD and PhD degrees, who have a clinical background in the field of pediatrics, pediatric neurology, pediatric surgery or child psychiatry and a long-term interest to combine clinical work and research. Adjunct professors (docents) or professors are not eligible to apply. During 2018, successful applicants will be 50-100% (depending on individual circumstances) involved in research conducted at the Academic Medical Center Helsinki. Applications will be sent to This email address is being protected from spambots. You need JavaScript enabled to view it. no later than Nov 24, 2017.

How to apply: The call is open from Oct 24 to Nov 24, 2017. Applications (as a single PDF file) will include

-Abstract (max. 1 page) and Research plan (max. 5 pages + 2 pages references) prepared according to the Academy of Finland guidelines, including a paragraph on career stage

-Applicant’s list of publications with impact factors              

-Applicant’s CV (max. 2 pages)

If you have questions related to technical details, please contact This email address is being protected from spambots. You need JavaScript enabled to view it.. If you have other questions related to this call, please contact Prof. Taneli Raivio at This email address is being protected from spambots. You need JavaScript enabled to view it..